85 related articles for article (PubMed ID: 19018861)
1. Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis.
Buxhofer-Ausch V; Gisslinger H; Berg T; Gisslinger B; Kralovics R
Eur J Haematol; 2009 Feb; 82(2):161-3. PubMed ID: 19018861
[No Abstract] [Full Text] [Related]
2. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
3. Combining interferon-alpha2b (IFN) and intravenous immunoglobulins IgG, IgM and IgA (IVIG) in rapid progressive myelofibrosis (MF) with Trisomy 1.
Rewald E; de las Mercedes Francischetti
Am J Hematol; 1997 Apr; 54(4):340. PubMed ID: 9092696
[No Abstract] [Full Text] [Related]
4. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Tefferi A; Lasho TL; Mesa RA; Pardanani A; Ketterling RP; Hanson CA
Leukemia; 2007 Aug; 21(8):1827-8. PubMed ID: 17460705
[No Abstract] [Full Text] [Related]
5. Isoderivative of deleted chromosome 20 in primary myelofibrosis (PMF) characterized by molecular cytogenetics and array CGH.
Douet-Guilbert N; Andrieux J; Laï JL; Morice P; Demory JL; Basinko A; Ugo V; Gueganic N; Le Bris MJ; Morel F; De Braekeleer M
Ann Hematol; 2009 Nov; 88(11):1157-9. PubMed ID: 19444446
[No Abstract] [Full Text] [Related]
6. Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon.
Domingues MA; Haepers AT; Massaut IH; Vassallo J; Lorand-Metze I
Haematologica; 1998 Dec; 83(12):1124-5. PubMed ID: 9949632
[TBL] [Abstract][Full Text] [Related]
7. [Chromosome abnormality 20q- in primary acquired sideroblastic anemia].
Nishigaki H; Okuda T; Horiike S; Yashige H; Yokota S; Kataoka K; Taniwaki M; Misawa S; Takino T; Inazawa J
Nihon Ketsueki Gakkai Zasshi; 1988 Aug; 51(5):825-31. PubMed ID: 3061271
[No Abstract] [Full Text] [Related]
8. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.
Silver RT; Vandris K
Leukemia; 2009 Jul; 23(7):1366-9. PubMed ID: 19440212
[No Abstract] [Full Text] [Related]
9. A novel cytogenetic abnormality in primary myelofibrosis.
Bae SY; Kim JS; Lee KN; Lee CK; Kim YK; Yoon SY; Lim CS; Cho YJ; Choi CW; Kim WY
Cancer Genet Cytogenet; 2009 Oct; 194(1):65-6. PubMed ID: 19737657
[No Abstract] [Full Text] [Related]
10. Chromosomal marker 20q- in cases of osteomyelosclerosis and CML.
Fleischman EW; Prigogina EL; Volkova MA; Kulagina OE
Hum Genet; 1979; 50(1):101-4. PubMed ID: 288724
[TBL] [Abstract][Full Text] [Related]
11. A myeloproliferative disorder may hide another one.
Laibe S; Tadrist Z; Arnoulet C; Sainty D; Mozziconacci MJ
Leuk Res; 2009 Aug; 33(8):1133-6. PubMed ID: 19250672
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
13. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
14. A unifying diagnosis for pancytopenia, fever, hypoglycemia, and lactic acidosis.
Kloesel B; Vaidya R; Howard MT; Thompson CA
Am J Hematol; 2013 Jan; 88(1):78-81. PubMed ID: 22460726
[No Abstract] [Full Text] [Related]
15. The translocation (4;12)(q31;q21) in myelofibrosis associated with myelodysplastic syndrome: impact of the 12q21 breakpoint.
Nunoda K; Sashida G; Ohyashiki K; Kodama A; Fukutake K
Cancer Genet Cytogenet; 2006 Jan; 164(1):90-1. PubMed ID: 16364771
[No Abstract] [Full Text] [Related]
16. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia.
Strasser-Weippl K; Steurer M; Kees M; Augustin F; Tzankov A; Dirnhofer S; Fiegl M; Gisslinger H; Zojer N; Ludwig H
Blood; 2005 May; 105(10):4146. PubMed ID: 15867421
[No Abstract] [Full Text] [Related]
17. Interferon alpha-2b in the treatment of myelofibrosis.
Furesi L; Laghi Pasini F; Forconi S
Haematologica; 1990; 75(6):587-9. PubMed ID: 2098307
[No Abstract] [Full Text] [Related]
18. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
19. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
20. Alpha interferon in primary myelofibrosis.
Turri D; Mitra ME; Di Trapani R; Cajozzo A
Haematologica; 1989; 74(4):417-8. PubMed ID: 2507422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
